The ADAM22 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the human ADAM22 gene in the HeLa cervical adenocarcinoma cell line. This loss-of-function model provides a versatile resource for investigating ADAM22-mediated cellular mechanisms, circumventing the need for individual clone isolation. The heterogeneous editing outcomes within the polyclonal pool ensure a broad representation of functional knockouts, enabling robust phenotypic screening and molecular analysis.
The HeLa host cell line, originally isolated from HPV-18 positive adenocarcinoma, is characterized by p53 inactivation via E6-mediated degradation, aneuploid genome, and rapid proliferation. These attributes have established HeLa as a workhorse for cancer research, heterologous protein expression, and signal transduction studies. The cell line??s high transfectability and well-documented culture protocols facilitate efficient delivery of CRISPR/Cas9 components and reliable post-editing experimental workflows, making it an optimal platform for generating polyclonal knockouts.
ADAM22 functions as a non-catalytic adhesion receptor that is central to the LGI1-ADAM22 signaling axis, governing AMPA receptor (AMPAR) trafficking at post-synaptic densities. It directly interacts with stargazin (CACNG2) and the scaffold protein DLG4 (PSD-95) to modulate surface expression of AMPAR subunits GluA1-4. LGI1 binding to ADAM22 is required for proper AMPAR localization; disruption of ADAM22 ablates this regulatory step, leading to deficient AKT signaling and reduced excitatory synaptic transmission. These molecular defects recapitulate key features of autosomal dominant lateral temporal lobe epilepsy (ADLTE), underscoring ADAM22??s pathogenic relevance.
In the HeLa cellular context, the ADAM22 knockout model offers a simplified system to dissect LGI1-ADAM22 downstream pathways free from the complexities of neuronal synaptic architecture. While HeLa cells do not assemble functional synapses, they enable precise biochemical interrogation of ADAM22??s interactions with CACNG2, DLG4, and AMPAR subunits upon LGI1 stimulation. This approach facilitates the mapping of signaling cascades, such as AKT activation, and the identification of potential regulatory checkpoints that may be targeted to correct aberrant trafficking in epilepsy disorders.
Researchers can employ this polyclonal knockout cell pool in diverse assay formats, including western blotting for protein expression analysis, RT-qPCR for transcriptional profiling, co-immunoprecipitation to confirm protein complexes, immunofluorescence to visualize subcellular localization, flow cytometry for population analysis, and cell adhesion assays to evaluate receptor function. Primary applications encompass epilepsy disease modeling, validation of LGI1-ADAM22 interaction inhibitors, and mechanistic studies of AMPAR cell surface dynamics. For additional technical data, please contact Ascent Research.
